MOLN Investor Relations & Company Overview - Molecular Partners AG

Watchlist Manager

Watchlist

Price: 3.07 CHF 0.33% Market Closed

Market Cap: CHf123.9m

	Molecular Partners AG SIX:MOLN	CH
	Sound Energy PLC LSE:SOU	UK
B	Barclays PLC XETRA:BCY	UK
	Bally's Corp NYSE:BALY	US
	Aviva PLC LSE:AV	UK
V	Vext Science Inc XMUN:VV5	CA
C	Capitec Bank Holdings Ltd JSE:CPI	ZA
I	ideaForge Technology Ltd NSE:IDEAFORGE	IN
	Delta Electronics Inc TWSE:2308	TW
M	Masco Corp DUS:MSQ	US
	Aedifica NV OTC:AEDFF	BE
	Solesence Inc NASDAQ:SLSN	US
M	MetroGAS SA BCBA:METR	AR
	Gaotu Techedu Inc NYSE:GOTU	CN
V	Volkswagen AG SWB:VOW	DE
	Informa PLC LSE:INF	UK
	Ashley Services Group Ltd ASX:ASH	AU
Y	Yext Inc F:0YE	US
	Lion Corp OTC:LIOPY	JP
S	Sony Group Corp XMUN:SON1	JP
	Guaranty Trust Holding Company PLC LSE:GTCO	NG
	PDD Holdings Inc NASDAQ:PDD	CN

Company Overview

Business Description

Sector: Health Care
Industry: Biotechnology
Headquarters: Switzerland CH
Employees: 134
IPO date: Oct 22, 2014

Molecular Partners is a Swiss biotechnology company that develops DARPin drugs, which are lab-made protein binders designed to attach tightly to disease targets. Its work centers on turning these engineered molecules into medicines for cancer and other serious diseases, with a heavy focus on treatments that can be given as targeted therapies rather than broad chemical drugs.

The company does not sell consumer products. It makes money mainly by advancing its drug candidates through research, clinical development, and partnerships with larger pharmaceutical companies. In this model, Molecular Partners can receive research funding, milestone payments, and royalties if partnered programs succeed, while also trying to build value in its own pipeline of experimental medicines.

What makes the business different is the DARPin technology itself. Instead of using traditional antibodies or small-molecule drugs, Molecular Partners builds custom proteins that can be tuned for specific targets and combinations of targets. That gives it a place as a technology-driven drug developer and a potential partner for companies looking for highly selective biologic therapies.

Molecular Partners AG Investor Relations

Wagistrasse 14

Schlieren, Zuerich

Switzerland

+41447557700 www.molecularpartners.com

Business Segments

Unlock Business Segments

DARPin drug development

This is the company’s main biotech business. It uses its DARPin protein platform to discover and develop medicines that are designed to bind to specific disease targets, mainly in cancer and other serious illnesses.

Customers

Patients are the end users, but the direct buyers are usually hospitals, doctors, and health systems once a medicine is approved.

Revenue Model

The company aims to earn money from future product sales, and from milestone and royalty payments if partner programs reach the market.

Partnered research

The company also works with pharmaceutical partners on selected DARPin programs and platform projects, helping design and advance new drug candidates.